Breaking News

Financial Report: AbbVie

February 1, 2016

Humira revenues up 11% in the quarter

4Q Revenues: $6.4 billion (+17%)

4Q Earnings: $1.5 billion (loss of $810 million 4Q14)

FY Revenues: $22.9 billion (+15%)

FY Earnings: $5.1 billion (+190%)

Comments: Humira revenues were $3.7 billion in the quarter, up 11%. Growth in the quarter was also driven by Imbruvica sales of $343 million, Viekira sales of $554 million, and Creon sales of $185 million. Lupron sales were $235 million, up 13%. Synagis sales were down 11% to $266 million. Kaletra sales were down 9% to $185 million. AndroGel sales were down 16% to $194 million. 2014 earnings were impacted by the Shire termination.
blog comments powered by Disqus
  • Staying Ahead in the Small Molecule Space

    Staying Ahead in the Small Molecule Space

    Dr. Matthew Moorcroft, VP Global Marketing, Cambrex||September 8, 2016
    Understand what is happening in the market and react accordingly

  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • Patent Law  and Contract Manufacturing

    Patent Law and Contract Manufacturing

    Beverly W. Lubit, Member of the Firm, Chiesa Shahinian & Giantomasi||September 8, 2016
    Analyzing the impact of The Medicines Co. vs. Hospira Inc. decision